{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:10:22Z","timestamp":1785345022136,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15932-4","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T12:14:50Z","timestamp":1774786490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ATRA plus arsenic trioxide versus ATRA plus chemotherapy in newly diagnosed acute promyelocytic leukemia: a grade-assessed systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0139-7166","authenticated-orcid":false,"given":"Hassan","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathimathul","family":"Henna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3739-415X","authenticated-orcid":false,"given":"Sana","family":"Khurram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3181-1872","authenticated-orcid":false,"given":"Ayesha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2779-7211","authenticated-orcid":false,"given":"Alisha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2914-6943","authenticated-orcid":false,"given":"Muhammad Hasnain","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4333-5793","authenticated-orcid":false,"given":"Mohammad Aitzaz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyal","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sher","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1624-208X","authenticated-orcid":false,"given":"Ali Abdul","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8043-884X","authenticated-orcid":false,"given":"Ashfaq","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"6","key":"15932_CR1","first-page":"1221","volume":"102","author":"A Sharma","year":"2023","unstructured":"Sharma A, Choudhary S, Khoury JD, Pemmaraju N. Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States. Ann Hematol. 2023;102(6):1221\u201330.","journal-title":"Ann Hematol"},{"issue":"1","key":"15932_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3324\/haematol.2011.046490","volume":"97","author":"JS McClellan","year":"2012","unstructured":"McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133\u20136.","journal-title":"Haematologica"},{"issue":"5","key":"15932_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","volume":"118","author":"JH Park","year":"2011","unstructured":"Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248\u201354.","journal-title":"Blood"},{"issue":"2","key":"15932_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"15932_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(5):605\u201312.","journal-title":"J Clin Oncol"},{"issue":"22","key":"15932_CR6","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","volume":"6","author":"HY Wang","year":"2022","unstructured":"Wang HY, Gu ZH, Yang QY, Chen Q, Zhang TT, Wang M, et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for the treatment of high-risk acute promyelocytic leukemia. Blood Adv. 2022;6(22):5857\u201368.","journal-title":"Blood Adv"},{"issue":"2","key":"15932_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/bjh.18618","volume":"201","author":"C Singh","year":"2023","unstructured":"Singh C, Jain S, Sharma A, Bansal A, Kumar S, Bharadwaj V, et al. Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy. Br J Haematol. 2023;201(2):232\u201340.","journal-title":"Br J Haematol"},{"issue":"7","key":"15932_CR8","doi-asserted-by":"publisher","first-page":"e0158760","DOI":"10.1371\/journal.pone.0158760","volume":"11","author":"Y Chen","year":"2016","unstructured":"Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, et al. All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis. PLoS ONE. 2016;11(7):e0158760.","journal-title":"PLoS ONE"},{"issue":"42","key":"15932_CR9","first-page":"69304","volume":"7","author":"J Huang","year":"2016","unstructured":"Huang J, Sun M, Wang Z, Zhang Q, Lou J, Cai Y, et al. Induction treatments for acute promyelocytic leukemia: a network meta-analysis. Oncotarget. 2016;7(42):69304\u201314.","journal-title":"Oncotarget"},{"issue":"9","key":"15932_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.leukres.2011.06.002","volume":"35","author":"H Wang","year":"2011","unstructured":"Wang H, Chen XY, Wang BS, Rong ZX, Qi H, Chen HZ. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res. 2011;35(9):1170\u20137.","journal-title":"Leuk Res"},{"key":"15932_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published March 28, 2021. https:\/\/doi.org\/10.1136\/bmj.n71. PubMed PMID: 33782057.","DOI":"10.1136\/bmj.n71"},{"key":"15932_CR12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. Published August 27, 2019. PubMed PMID: 31462587.","journal-title":"BMJ"},{"issue":"7414","key":"15932_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557. PMID: 12958120; PMCID: PMC192859.","journal-title":"BMJ"},{"issue":"29","key":"15932_CR14","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO-25-00535","volume":"43","author":"U Platzbecker","year":"2025","unstructured":"Platzbecker U, Ad\u00e8s L, Montesinos P, Ammatuna E, Fenaux P, Baldus C, et al. Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute promyelocytic leukemia: Results from the apollo trial. J Clin Oncol. 2025;43(29):3160\u20139.","journal-title":"J Clin Oncol"},{"key":"15932_CR15","doi-asserted-by":"crossref","unstructured":"Chen L, Zhu HM, Li Y, Liu QF, Hu Y, Zhou JF, et al. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proceedings of the National Academy of Sciences. 2021;118(6):e2020382118.","DOI":"10.1073\/pnas.2020382118"},{"issue":"13","key":"15932_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomized, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295\u2013305.","journal-title":"Lancet Oncol"},{"key":"15932_CR17","doi-asserted-by":"publisher","unstructured":"Lebon D, Da Rocha A, Cassinat B, Heiblig M, Bertoli S, Bonmati C, et al. Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia: Acute Myeloid Leukemia. Leukemia. 2025;39(8):1865\u201370. https:\/\/doi.org\/10.1038\/s41375-025-02663-x. Epub 2025 Jun 24. PMID: 40555732.","DOI":"10.1038\/s41375-025-02663-x"},{"key":"15932_CR18","unstructured":"Chen H, Wang X, Huang T, Liu J, Shen Y, Feng Y, et al. Early application of arsenic trioxide improved the clinical outcomes of acute promyelocytic leukemia. Vol 10. International Journal of Clinical and Experimental Medicine. 2017;10:14579\u201385."},{"issue":"4","key":"15932_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1182\/bloodadvances.2024014999","volume":"9","author":"H Gill","year":"2025","unstructured":"Gill H, Raghupathy R, Hou HA, Cheng-Hong Tsai X, Tantiworawit A, Ooi MG, et al. Acute promyelocytic leukemia asian consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome. Blood Adv. 2025;9(4):862\u201376.","journal-title":"Blood Adv"},{"issue":"9","key":"15932_CR20","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/s41375-020-0758-4","volume":"34","author":"S Kayser","year":"2020","unstructured":"Kayser S, Rahm\u00e9 R, Mart\u00ednez-Cuadr\u00f3n D, Ghiaur G, Thomas X, Sobas M, et al. Outcome of older (\u2265\u200970 years) APL patients frontline treated with or without arsenic trioxide\u2014an international collaborative study. Leukemia. 2020;34(9):2333\u201341.","journal-title":"Leukemia"},{"issue":"1","key":"15932_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/hon.2076","volume":"32","author":"Y Lou","year":"2014","unstructured":"Lou Y, Qian W, Meng H, Mai W, Tong H, Tong Y, et al. Long-term efficacy of low\u2010dose all\u2010trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post\u2010remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematol Oncol. 2014;32(1):40\u20136.","journal-title":"Hematol Oncol"},{"issue":"5","key":"15932_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.4103\/jcrt.jcrt_436_21","volume":"19","author":"M Saxena","year":"2023","unstructured":"Saxena M, Madabhavi IV, Patel A, Panchal H, Anand A. Treating low-and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: a comparison in a tertiary care center. J Cancer Res Ther. 2023;19(5):1371\u20138.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"15932_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/10428194.2018.1504941","volume":"60","author":"S Tao","year":"2019","unstructured":"Tao S, Wang C, Chen Y, Deng Y, Song L, Shi Y, et al. Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia. Leuk Lymphoma. 2019;60(3):711\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"15932_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2024026186","volume":"145","author":"MT Voso","year":"2025","unstructured":"Voso MT, Guarnera L, Lehmann S, D\u00f6hner K, D\u00f6hner H, Platzbecker U, et al. Acute promyelocytic leukemia: long-term outcomes from the harmony project. Blood. 2025;145(2):234\u201343.","journal-title":"Blood"},{"issue":"7","key":"15932_CR25","doi-asserted-by":"publisher","first-page":"e0158760","DOI":"10.1371\/journal.pone.0158760","volume":"11","author":"Y Ma","year":"2016","unstructured":"Ma Y, Liu L, Jin J, Lou Y. All-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysis. PLoS ONE. 2016;11(7):e0158760.","journal-title":"PLoS ONE"},{"issue":"26","key":"15932_CR26","first-page":"39700","volume":"7","author":"F Wu","year":"2016","unstructured":"Wu F, Wu D, Ren Y, et al. Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia. Oncotarget. 2016;7(26):39700\u201313.","journal-title":"Oncotarget"},{"issue":"4","key":"15932_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775\u201383.","journal-title":"Blood"},{"issue":"19","key":"15932_CR28","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","volume":"21","author":"JT Barbey","year":"2003","unstructured":"Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced acute promyelocytic leukemia. J Clin Oncol. 2003;21(19):3609\u201315.","journal-title":"J Clin Oncol"},{"issue":"15","key":"15932_CR29","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630\u201343.","journal-title":"Blood"},{"issue":"11","key":"15932_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de Th\u00e9","year":"2010","unstructured":"de Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"15932_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm.1891","volume":"14","author":"R Nasr","year":"2008","unstructured":"Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008;14(12):1333\u201342.","journal-title":"Nat Med"},{"issue":"7","key":"15932_CR32","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","volume":"107","author":"V Mathews","year":"2006","unstructured":"Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627\u201332.","journal-title":"Blood"},{"issue":"5","key":"15932_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0272989X13485156","volume":"33","author":"AE Ades","year":"2013","unstructured":"Ades AE, Caldwell DM, Reken S, et al. Evidence synthesis for decision making 7: a reviewer\u2019s checklist. Med Decis Mak. 2013;33(5):679\u201391.","journal-title":"Med Decis Mak"},{"key":"15932_CR34","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"15932_CR35","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated 2024). London: Cochrane; 2024. Available from: https:\/\/training.cochrane.org\/handbook."},{"issue":"7","key":"15932_CR36","first-page":"1694","volume":"59","author":"JM Li","year":"2018","unstructured":"Li JM, Shen ZY, Loose T, et al. Regional variation in APL outcomes: a pooled analysis. Leuk Lymphoma. 2018;59(7):1694\u2013701.","journal-title":"Leuk Lymphoma"},{"key":"15932_CR37","volume-title":"NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Version 4.2024","author":"National Comprehensive Cancer Network","year":"2024","unstructured":"National comprehensive cancer network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Version 4.2024. Fort Washington (PA): NCCN; 2024."},{"issue":"4","key":"15932_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","volume":"27","author":"F Ravandi","year":"2009","unstructured":"Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504\u201310.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15932_CR39","first-page":"e184","volume":"5","author":"HH Zhu","year":"2018","unstructured":"Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomized phase 3 trial. Lancet Haematol. 2018;5(4):e184\u201392.","journal-title":"Lancet Haematol"},{"issue":"22","key":"15932_CR40","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15932_CR41","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/cncr.31327","volume":"124","author":"H Gill","year":"2018","unstructured":"Gill H, Kumana CR, Yim R, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study. Cancer. 2018;124(11):2316\u201326.","journal-title":"Cancer"},{"issue":"9","key":"15932_CR42","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","volume":"107","author":"EH Estey","year":"2006","unstructured":"Estey EH, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469\u201373.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15932-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:52:33Z","timestamp":1778543553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15932-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15932"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15932-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"597"}}